82 results about "Insulin resistance" patented technology

The invention provides a composition for assisting in reducing blood sugar and improving insulin resistance and a preparation method of the composition, and relates to the technical field of functional fiber processing. The composition for assisting in reducing blood sugar and improving insulin resistance comprises the following raw materials in parts by weight: 10-15 parts of depolymerization type composite cereal fibers, 3-5 parts of konjac fibers, 3-5 parts of psyllium husk powder, 2-3 parts of sesame powder, 1-2 parts of xylitol and 0.1-0.5 part of vitamin C, the mass ratio of wheat fiber to corn fiber to sweet potato fiber to pea fiber in the depolymerization type composite grain fiber is (25-30): (35-40): (20-25): (10-15). The composition disclosed by the invention can assist in reducing blood sugar and has a good effect of improving insulin resistance.

The invention belongs to the technical field of biological medicines, and particularly relates to application of 1, 3-propane diamine or pharmaceutically acceptable salts thereof in preparation of medicines for preventing or treating diabetes. Experimental results show that 1, 3-propane diamine can obviously improve random blood glucose and fasting blood glucose of mice with type 2 diabetes mellitus, and 1, 3-propane diamine can obviously improve insulin resistance of model mice. According to the application, 1, 3-propane diamine is used for improving the blood sugar of patients with type 2 diabetes for the first time, an ideal treatment effect is achieved, a new treatment choice is provided for improving the blood sugar level through clinical application of 1, 3-propane diamine, and the application has extremely high application value and social benefits.

The invention provides an application of liquiritin in preparation of a PPAR gamma receptor partial agonist. Through a structure-based high-throughput virtual screening technology, it is found that liquiritin can be used as a partial agonist of a PPAR gamma receptor, and the relative activation efficiency of liquiritin is 35.9% of that of rosiglitazone; in-vitro experiments prove that liquiritin can remarkably promote glucose uptake and consumption of HepG2 cells and does not induce adipocyte differentiation; in-vivo experiments prove that liquiritin can effectively improve the blood glucose level of an insulin resistance mouse model induced by high fat diet and reduce the level of serum proinflammatory factors. Compared with thiazolidinedione compounds, liquiritin not only can relieve and treat insulin resistance or related metabolic diseases, but also does not cause adverse reactions such as weight gain, fat accumulation and myocardial hypertrophy, provides a new candidate compound for developing safe and effective anti-diabetic drugs, and has a wide application prospect.

The invention provides a tea composition capable of reducing blood sugar as well as a preparation method and application of the tea composition, and belongs to the technical field of tea compositions. The tea comprises the following raw materials in parts by weight: 1-5 parts of white tea, 1-9 parts of roses, 1-9 parts of guava leaf tea, 1-5 parts of mulberry leaves, 1-5 parts of ampelopsis grossedentata and 1-5 parts of cyclocarya paliurus. The tea has the effects of reducing postprandial blood sugar, stabilizing and controlling sugar, relaxing bowel, relieving constipation and reducing weight, and tea soup is rich in fragrance, pure in taste and long in aftertaste. According to the invention, chronic disease management requirements can be provided for patients with chronic diseases such as insulin resistance, diabetes mellitus and long-term constipation, and significant benefits are brought to health management. The traditional Chinese medicine composition can relieve the medical resource pressure caused by lifelong medication of diabetic patients at present, improves the life quality of the patients, and provides an example for exploring the application of natural medicines in chronic disease treatment.

A computing system, a computer implemented method, and a wearable computing device to predict insulin resistance in a wearer of the wearable computing device without requiring additional invasive testing other than test data that may already be available, although not required, is provided. For instance, a machine-learned model is trained to predict insulin resistance in the wearer of the wearable computing device based at least in part on non-invasive biometric data associated with the wearer. Then, one or more non-transitory computer-readable media cause the computing system to perform operations via one or more processors. The operations include receiving the non-invasive biometric data from one or more sensors associated with the wearable computing device; and implementing the machine-learned model to determine if the non-invasive biometric data associated with the wearer is indicative of insulin resistance.

Provided is a use of Staphylococcus lentus with an accession number of GDMCC 1.247 in preparation of a composition for preventing and treating insulin resistance or type 2 diabetes. This strain can significantly reduce the weight gain induced by a high-fat diet (HFD), improve the glucose tolerance, promote the insulin secretion, improve the insulin resistance, and significantly improve the immunity and inflammation.

The invention discloses polygonatum cyrtonema polysaccharide as well as a preparation method and application thereof, and relates to the technical field of plant polysaccharide extraction. The invention relates to the technical field of biological medicine, in particular to polygonatum cyrtonema polysaccharide as well as a preparation method and application thereof. The polygonatum cyrtonema polysaccharide is composed of fructose and glucose according to the molar ratio of 27.5: 1, the main chain of the polygonatum cyrtonema polysaccharide is of a 1-beta-D-Fruf-(2-) structure, and the side chain of the polygonatum cyrtonema polysaccharide comprises-> 6-beta-D-Fruf-(2-) and-> 1, 6-beta-D-Fruf-(2-). The polygonatum cyrtonema polysaccharide provided by the invention has the activity of reducing blood sugar, reducing blood fat and relieving insulin resistance, and has a wide application prospect in the aspect of developing functional foods or medicines for adjuvant therapy of diabetes mellitus.

The invention discloses a camelina sativa seed meal oligosaccharide extract capable of regulating blood sugar and a preparation method of the camelina sativa seed meal oligosaccharide extract, and the camelina sativa seed meal oligosaccharide extract is extracted from camelina sativa seed meal through fermentation, heating extraction, cooling alcohol precipitation and enzymolysis. Comprising a camelina seed meal oligosaccharide extract and a cortex fraxini iridoid component extract. The cortex fraxini iridoid component extract is obtained through microwave-assisted enzymolysis extraction and purification; the invention further discloses application of the blood sugar reducing composition in blood sugar reducing food, medicine or health care products. The camelina seed meal oligosaccharide extract, the cortex fraxini iridoid component extract and the hypoglycemic composition have inhibition ability on alpha-glucosidase and alpha-amylase, can improve glucose consumption, glycogen content and glycolysis key enzyme activity, effectively improve insulin resistance, improve oxidative stress, regulate intestinal flora structure, and improve the blood sugar level, so that the hypoglycemic effect of the composition is improved. The traditional Chinese medicine is safe and non-toxic and has a good effect on treating diabetes and complications.

The invention belongs to the field of functional substance research, and particularly relates to a corn extract for promoting GLP-1 secretion and a preparation method and application thereof. The corn extract provided by the invention is a dry product obtained by soaking dry powder of fresh corn kernels in ethanol or an ethanol water solution at room temperature and then performing ultrasonic extraction; the fresh corn comprises yellow and sweet corn; the temperature of the ultrasonic extraction is 30-60 DEG C; the power of the ultrasonic extraction is 50 to 150W; the ultrasonic extraction time is 30 to 90 minutes. The preparation method of the corn extract provided by the invention is simple and easy to implement, and the production cost of functional components can be effectively reduced. The corn extract provided by the invention can effectively promote intestinal L cells to secrete GLP-1 in a healthy state and an insulin-resistant state, and synchronously improve the cell viability.

The invention provides a specific full-nutrient formula food applied to diet-restricted diabetes mellitus groups, and belongs to the technical field of formula foods for special medical purposes. According to the product, marine active substances and medicinal and edible traditional Chinese medicine extracts are innovatively compounded, and a multi-probiotic microencapsulation technology is combined, so that a specific full-nutrition formula with the functions of regulating blood sugar, improving insulin resistance and protecting target organ functions is formed. The formula comprises marine active ingredients such as marine collagen tripeptide, a sea cucumber saponin extract and fucoidan as well as medicinal and edible traditional Chinese medicine extracts such as mulberry leaves, rhizoma polygonati and radix puerariae, and oligopeptide, amino acid, multivitamins and mineral substances in a specific proportion are matched. Probiotics are protected by adopting a three-layer microencapsulation technology to pass through a gastric acid environment, active ingredients are reserved by utilizing a low-temperature enzymolysis and molecular directed extraction technology, and the nutritional status and blood sugar control of diabetic patients can be remarkably improved through clinical verification. The product conforms to the GB 29922-2013 special medical purpose formula food standard, can be used as a single nutrition source for diabetics, and meets the special nutrition requirements of the diabetics.

The invention discloses a functional solid beverage capable of reducing fat, losing weight and conditioning five highs. According to the functional solid beverage, dietary fibers such as fructo-oligosaccharide, inulin and the like are used for regulating intestinal flora, a white kidney bean extract is used for inhibiting the activity of alpha-amylase, L-carnitine is used for promoting fat transport, and medicinal and edible components such as ginseng, lotus leaves and the like are matched to realize multi-way metabolism regulation. The weight percentage of each component can be adjusted within a specified range so as to adapt to different physique requirements. Animal experiments prove that the total cholesterol (TC) of serum can be obviously reduced by 21.3-25.8% and the triglyceride (TG) can be obviously reduced by 28.9-34.2% after the traditional Chinese medicine is continuously taken for 4 weeks, and meanwhile, the insulin resistance index (HOMA-IR) can be improved to 16.5-20.3%.

The present invention provides a method for preparing an animal model of insulin resistance and abnormal glucose metabolism caused by mild to moderate hypertriglyceridemia, by injecting poloxamer 407 solution into the mouse peritoneal cavity at a dose of 25-100 mg per kilogram of mouse, administering the drug once every other day for 12 consecutive weeks, and continuously monitoring blood lipid and blood glucose levels. The preferred dose of the present invention is 75 mg per kilogram of mouse. The present invention also provides the use of the animal model in screening and preparing drugs for treating insulin resistance and abnormal glucose metabolism caused by mild to moderate hypertriglyceridemia. The present invention simulates insulin resistance and abnormal glucose metabolism directly caused by mild to moderate hypertriglyceridemia. Compared with traditional high-fat diets or gene knockout models, triglyceride levels are precisely regulated by chemical intervention, avoiding factors such as obesity and inflammation and the risk of genetic manipulation, and having high controllability and efficiency.

The application discloses a composition containing burdock polysaccharide for reducing blood sugar of type 2 diabetes patients and a preparation method and application thereof, and belongs to the technical field of medicine and food. The composition contains burdock polysaccharide, chitooligosaccharide, chlorogenic acid, epicatechin, resveratrol, ginsenoside Rd, and vitamin D, vitamin B1, vitamin B6, vitamin B12, magnesium glycinate and thaumatin protein. The application takes burdock polysaccharide as a core long-acting component, takes chitooligosaccharide as a short-acting synergistic component, constructs a long-short-acting synergistic blood sugar reducing system, and realizes the organic combination of rapid blood sugar reduction and stable blood sugar control. Experiments show that the composition can significantly reduce the fasting blood sugar of type 2 diabetes model rats, improve insulin resistance and glucose tolerance, reduce blood lipid and inflammatory factor levels, and reduce oxidative stress damage. The alpha-glucosidase inhibitory activity and in-vivo comprehensive blood sugar reducing effect of the composition are better than those of single burdock polysaccharide, and the composition has good taste and is suitable for long-term use of diabetes patients.

The invention relates to the field of traditional Chinese medicine compositions, and particularly discloses a traditional Chinese medicine composition for detoxifying, dredging collaterals, eliminating paste and stabilizing sugar and a preparation method thereof. The traditional Chinese medicine composition is prepared from the following raw materials in parts by weight: 7 to 15g of rhizoma coptidis, 6 to 10g of wine-treated rhubarb, 15 to 30g of radix astragali seu hedysari, 12 to 15g of radix salviae miltiorrhizae, 12 to 20g of radix paeoniae rubra, 6 to 10g of radix bupleuri, 6 to 10 parts of herba artemisiae scopariae, 7 to 15 parts of fructus crataegi and 7 to 15 parts of pericarpium citri reticulatae. The detoxifying, collateral dredging, ointment eliminating and sugar stabilizing traditional Chinese medicine composition can achieve the effects of reducing blood sugar fluctuation and lipid deposition on the basis of achieving the effects of reducing blood sugar and improving the insulin resistance level, can effectively reduce the dosage of compound medicine for a patient so as to improve the compliance of the patient, is safe and effective, delays the occurrence of diabetes complicated diseases and complications, and has a wide application prospect. And the living quality of the patient is improved.

A computing system, a computer implemented method, and a wearable computing device to predict insulin resistance in a wearer of the wearable computing device without requiring additional invasive testing other than test data that may already be available, although not required, is provided. For instance, a machine-learned model is trained to predict insulin resistance in the wearer of the wearable computing device based at least in part on non-invasive biometric data associated with the wearer. Then, one or more non-transitory computer-readable media cause the computing system to perform operations via one or more processors. The operations include receiving the non-invasive biometric data from one or more sensors associated with the wearable computing device; and implementing the machine-learned model to determine if the non-invasive biometric data associated with the wearer is indicative of insulin resistance.

The application belongs to the field of functional substance research, and particularly relates to a corn extract for promoting GLP-1 secretion, and a preparation method and application thereof. The corn extract provided by the application is a dried product obtained by ultrasonic extraction of a dried powder of fresh corn kernels after room temperature soaking in ethanol or an ethanol aqueous solution; the fresh corn comprises yellow sweet corn; the temperature of the ultrasonic extraction is 30-60 DEG C; the power of the ultrasonic extraction is 50-150 W; and the time of the ultrasonic extraction is 30-90 min. The preparation method of the corn extract is simple and easy to implement, and can effectively reduce the production cost of functional ingredients. The corn extract can effectively promote the secretion of GLP-1 by intestinal L cells in both healthy and insulin-resistant states, and simultaneously improve cell viability.

The invention relates to the technical field of diet recommendation, in particular to a diet recommendation method and system based on insulin resistance, and the system comprises a dynamic blood glucose monitor which is used for monitoring blood glucose in real time; the data acquisition module is used for establishing a blood glucose curve according to the acquired data; the analysis module is used for determining the diet condition of the monitoring main body based on the blood glucose curve; the recommendation module is used for adjusting the diet of the monitored subject based on the analysis result of the analysis module; the mobile terminal is used for enabling the monitoring main body to input food types and display diet regulation modes; the method comprises the steps of establishing a real-time blood glucose curve and standard blood glucose data, determining eligibility of the real-time blood glucose curve based on the real-time blood glucose curve and the standard blood glucose curve, calculating a fluctuation evaluation value based on the unqualified real-time blood glucose curve, and determining increase of dining duration, adjustment of dining share or shortening of dining interval time based on the fluctuation evaluation value. According to the invention, the accuracy of personalized diet recommendation is improved.

The invention provides application of an inhibitor of cathepsin D or a coding gene thereof in preparation of a product for preventing and / or treating type 2 diabetes mellitus. The inhibitor realizes prevention and / or treatment of the type 2 diabetes mellitus by inhibiting expression of the cathepsin D or the coding gene thereof or inhibiting activity of the cathepsin D; applications are achieved by administering an inhibitor of cathepsin D expression, an inhibitor of cathepsin D coding gene expression, or an inhibitor of cathepsin D activity. The inhibitor inhibits the activation of a JAK2-STAT3 signal channel by inhibiting the expression of cathepsin D or a coding gene thereof, or inhibiting the activity of cathepsin D, so as to prevent and / or treat type 2 diabetes mellitus. The cathepsin D disclosed by the invention can be used as a key molecular target for intervening liver insulin resistance for the first time, glycolipid metabolism disorder of a high-fat induced mouse model is remarkably improved by specifically inhibiting the activity of the cathepsin D, and a new strategy is provided for treating liver insulin resistance related diseases T2DM.

The invention discloses a traditional Chinese medicine composition for treating metabolism-related fatty liver diseases and application thereof, and belongs to the technical field of traditional Chinese medicines. The composition is prepared from 30 g of poria cocos, 30 g of rhizoma atractylodis macrocephalae, 30 g of radix salviae miltiorrhizae, 10 g of fructus crataegi, 15 g of pericarpium citri reticulatae, 15 g of lotus leaves, 10 g of rhizoma alismatis, 15 g of red yeast rice, 10 g of herba artemisiae scopariae and 10 g of emblic leafflower fruit according to The freeze-dried powder is prepared by adopting processes of three times of water extraction, low-temperature vacuum concentration and freeze drying, the extraction efficiency is about 37%, and active ingredients are completely reserved. Animal experiments show that the composition can significantly relieve obesity, improve liver fatty degeneration, reduce liver lipid deposition, repair liver injury, regulate dyslipidemia, improve glucose tolerance and insulin resistance, and inhibit liver lipid synthesis and inflammatory response; and no liver and kidney toxicity is caused by continuous high-dose use. The composition provided by the invention has the advantages of multiple targets, systematic regulation of metabolism, exact curative effect and high safety, and provides a novel effective traditional Chinese medicine scheme for prevention and treatment of metabolism-related fatty liver diseases.

The application discloses a compound cereal powder for controlling blood sugar and reducing blood sugar, a preparation method and application thereof. The compound cereal powder comprises, in percentage by weight, 10-30% of soybean dietary fiber, 10-25% of resistant dextrin, 5-20% of soybean protein isolate powder, 5-15% of oat powder, 5-15% of black bean powder, 3-12% of purple sweet potato powder, 3-12% of oatmeal, 0.5-5% of poria cocos powder, 0.5-5% of yam powder, 0.5-5% of honeysuckle powder, 1-8% of konjac powder, 0.5-5% of medlar powder, 0.5-5% of mulberry leaf powder, 0.5-5% of rhizoma polygonati powder, compound vitamins, calcium carbonate, zinc gluconate and sodium carboxymethyl cellulose. The preparation method comprises the following steps: low-temperature baking and curing cereal raw materials, uniformly mixing by a three-dimensional mixer, screening and sterilizing, and sterilely sub-packaging. The compound cereal powder controls blood sugar and reduces blood sugar through multiple mechanisms such as a dietary fiber physical barrier, alpha-glucosidase inhibition, improvement of insulin resistance and supplement of trace elements, is comprehensive in nutrition, good in taste, and is suitable for people with diabetes and pre-diabetes as a meal replacement or a functional food for assisting blood sugar reduction.

The invention discloses preparation of gleditsia sinensis polysaccharide and application of the gleditsia sinensis polysaccharide in products with functions of resisting oxidation and / or reducing blood sugar. According to the invention, Gleditsia sinensis Lam. Endosperm is used as a raw material, a green and efficient extraction technology is adopted to obtain purified Gleditsia sinensis Lam. Polysaccharide GSP-1, and the structure of the Gleditsia sinensis Lam. Polysaccharide GSP-1 is analyzed through high performance gel permeation chromatography, infrared spectroscopy, ion chromatography, gas chromatography-mass spectrometry and nuclear magnetic resonance spectroscopy. The GSP-1 has excellent antioxidation and hypoglycemic effects, promotes glucose consumption, promotes glucose metabolism, effectively improves insulin resistance, and has a positive promotion effect on regulating blood sugar and preventing and treating diabetes mellitus; the method has wide application prospects in the aspects of food processing, health care product development, functional food addition and the like for assisting in treating diabetes and controlling blood sugar, and has important significance in improving the added value of gleditsia sinensis, improving the scientific and technological innovation ability of agricultural products and driving industrial transformation and upgrading.

The application relates to the technical field of compound medicines, and discloses application of a compound external-use patch for preventing and treating diabetic peripheral neuropathy, wherein the compound external-use patch comprises a gel base and dry extract and volatile oil doped into the gel base, the dry extract and the volatile oil are derived from a compound, and the compound is composed of 10-20 parts of cinnamon, 8-12 parts of asarum, 8-12 parts of evodia, 8-12 parts of chuanxiong and 0.2-0.8 parts of borneol in terms of weight parts. The compound external-use patch of the application is locally pasted on acupoints or joints of DPN rats, can reduce the blood sugar level of diabetic peripheral neuropathy rats, increase the insulin level, improve insulin resistance, prolong the latent period of hot stimulation foot withdrawal, increase the nerve conduction velocity, maintain the normal morphology and function of nerve cells, and therefore can prevent and inhibit the generation and deterioration of diabetic peripheral neuropathy; and the compound external-use patch improves the safety and convenience of patients in taking medicine compared with oral medicine.

The application relates to the field of biological medicine, and discloses an application of pachyman-derived extracellular vesicles and high-abundance miRNA thereof in relieving obesity. Cell experiments and animal experiments find that the pachyman-derived extracellular vesicles and high-abundance miRNA thereof can up-regulate the expression amount of key genes for brownification of white fat in 3T3-L1 adipocytes and mice in vivo, significantly improve glucose tolerance and insulin resistance of obese mice, and obviously relieve liver steatosis and lipid accumulation. Not only can the pachyman-derived extracellular vesicles and high-abundance miRNA thereof improve obesity from a phenotype, but also can regulate lipid metabolism, and have the value of being applied to preparation of medicines for preventing or relieving obesity and related metabolic complications.

The invention specifically discloses application of RNA binding protein FXR1 as a target spot in preparation of products for preventing and treating metabolism-related fatty liver diseases and improving glucose and lipid metabolism disorders, and relates to the technical field of biological medicines. By constructing a liver specific knockout mouse (HKO) and high-fat and high-sugar diet induction model, the invention reveals that the RNA binding protein FXR1 is a key pathogenic factor for liver fatty degeneration and metabolic disorder for the first time, and discovers that the deletion of the RNA binding protein FXR1 can significantly improve liver lipid deposition, alleviate liver injury and fibrosis, and can be used for treating liver fatty degeneration and metabolic disorder. The invention can improve the abnormal glucose tolerance and insulin resistance of the whole body, and inhibit the RNA binding protein FXR1 as a new strategy for treating liver glycolipid metabolism and metabolism-related fatty liver diseases.

The invention discloses a rhizoma polygonati composite tablet candy capable of regulating blood sugar and a preparation method thereof, and the rhizoma polygonati composite tablet candy is prepared from the following components in parts by mass: 400-600 parts of a rhizoma polygonati extract, 40-60 parts of a hawthorn extract, 20-40 parts of galactooligosaccharide, 20-40 parts of whey protein peptide, 10-30 parts of a fructus momordicae extract, 10-20 parts of a bitter gourd extract and 1-10 parts of a mint extract. And 1-5 parts of mulberry leaf extract. The rhizoma polygonati extract and the bitter gourd extract are added into the tabletted candy, so that the blood sugar of an eater can be improved, and the insulin resistance can be improved; 1-deoxynojirimycin, mogroside and whey protein peptide are added into the tabletted candy, so that the astringent taste in the rhizoma polygonati extract can be neutralized, and the bitter taste in the bitter gourd extract can be neutralized by adding the mint extract, so that the taste during eating is improved; and each tablet does not need to be packaged independently in the form of the tablet candy, so that the packaging and transportation costs of manufacturers are reduced, and consumers can carry and eat the tablet candy conveniently.

The invention provides gynura divaricata polysaccharide as well as a preparation method and application thereof, and belongs to the field of polysaccharide preparation. The homogeneous component GDP1 of the gynura divaricata polysaccharide is mainly prepared from fructose, glucose, arabinose and galactose according to the molar ratio of 58.4: 39.08: 0.75: 0.78; the molecular weight Mw is 6684Da, and the purity is 99.04%; t2DM mouse in-vivo hypoglycemic activity research is carried out, and the prepared gynura divaricata polysaccharide can relieve the symptom of weight loss of mice, relieve the hyperglycemia and insulin resistance level of the mice and regulate the abnormal conditions of the blood fat level, the oxidative stress level and the inflammation level of the mice. The PI3K / Akt / GLUT-4 signal channel is activated to increase the glucose uptake of the T2DM mouse and reduce the insulin resistance of the T2DM mouse, so that the blood glucose metabolism of the T2DM mouse is improved. The gynura divaricata polysaccharide can be used for preparing medicines for treating type 2 diabetes mellitus.

In an approach to estimating diabetes risk, the present invention receives a biomarker signal over a first period of time. From the biomarker signal, the presently claimed invention extracts one or more features of the biomarker signal and determines a first trend associated with insulin resistance based on the one or more features of the biomarker signal. Using this information, the present invention can determine a relative non-digestion-related contribution to the blood glucose signal and / or a relative digestion-related contribution to the blood glucose signal is determined based on the one or more features extracted from the blood glucose signal. In some cases, an absolute digestion related contribution and / or an absolute non-digestion- related contribution is determined from the relative digestion-related and non-digestion-related contribution.

The application provides a use of biomarkers in the preparation of a product for TCM syndrome typing of a type 2 diabetes mellitus patient combined with metabolic syndrome, and / or for evaluating the risk of cognitive impairment of a type 2 diabetes mellitus patient combined with metabolic syndrome, wherein the biomarkers are selected from one or more of SERPINA3, BACE1 or CXCL1. The serum SERPINA3, BACE1 and CXCL1 levels are related to TCM syndrome types, provide a laboratory basis for TCM syndrome differentiation and treatment, help to improve the accuracy and standardization of TCM diagnosis, and according to the serum index levels and characteristics, a personalized treatment plan is formulated. Secondly, the serum index has predictive value for cognitive impairment, which helps to identify high-risk patients early and delay cognitive decline. For patients with a long course and poor blood glucose control, the serum index level can be regularly detected, combined with clinical indications, and timely anti-inflammatory, nerve nutrition and insulin resistance improvement treatment is given to protect cognitive function.

The invention relates to a children insulin resistance risk prediction method and a computer readable storage medium, the children insulin resistance risk prediction method comprises a machine learning model and an interpretable algorithm, the machine learning model is constructed based on children obesity related variables, the interpretable algorithm is integrated in the machine learning model, and the interpretable algorithm comprises a first algorithm and a second algorithm. The first algorithm is used for screening key obesity-related variables influencing the insulin resistance of the children from the obesity-related variables of the children, and the second algorithm is used for analyzing the synergistic effect of each key obesity-related variable on the insulin resistance of the children. Compared with the prior art, the method has important significance on prevention and management of the IR, and the risk of IR occurrence is reduced by intervening and adjusting related variable indexes of obesity of children. In addition, the method is beneficial to formulating a personalized nursing plan from the perspective of children obesity related variables, and functions are deployed on an open source website, so that pediatricians, parents and children can use the system conveniently.

The invention discloses a cognitive disorder occurrence risk prediction method, device and equipment and a medium. The prediction method comprises the following steps: acquiring multi-dimensional obesity phenotype information and insulin resistance indexes of a subject; inputting the multi-dimensional obesity phenotype information and the insulin resistance indexes into a pre-trained cognitive disorder risk prediction model; based on the output of the model, obtaining a cognitive disorder occurrence risk prediction result of the subject; wherein the multi-dimensional obesity phenotype information comprises a systemic obesity index and a central obesity index, and the insulin resistance index is calculated based on a blood detection index in conventional physical examination. It is found that although a single obesity index or a single insulin resistance index has a certain cognitive impairment prediction capability, a higher and more stable cognitive impairment prediction capability can be obtained by integrating multi-dimensional obesity phenotype information and the insulin resistance index. The technical scheme of the invention can be applied to various scenes such as hospital physical examination systems, primary medical follow-up visit, old-age community health management and the like.